we keep life real and safe by providing botanical-dna based security and authentication solutions and services that protect assets, products, brands, supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Company profile
Ticker
APDN, APPDW
Exchange
Website
CEO
James Hayward
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
DATALINK CAPITAL CORP/TX/, DCC ACQUISITION CORP, PROHEALTH MEDICAL TECHNOLOGIES INC
SEC CIK
Corporate docs
Subsidiaries
APDN (B.V.I.) Inc. • Applied DNA Sciences Europe Limited • Applied DNA Sciences India Private Limited • LineaRX, Inc. • Applied DNA Clinical Labs LLC • Spindle Biotech, Inc. ...
IRS number
592262718
APDN stock data
Latest filings (excl ownership)
8-K
Applied DNA Announces Fourth Quarter Fiscal Year 2023
7 Dec 23
10-K
2023 FY
Annual report
7 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
6 Dec 23
8-K
Entry into a Material Definitive Agreement
7 Nov 23
424B5
Prospectus supplement for primary offering
7 Nov 23
8-K
Submission of Matters to a Vote of Security Holders
20 Sep 23
8-K
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
10 Aug 23
10-Q
2023 Q3
Quarterly report
10 Aug 23
DEFA14A
Additional proxy soliciting materials
7 Aug 23
DEF 14A
Definitive proxy
7 Aug 23
Transcripts
APDN
Earnings call transcript
2023 Q4
7 Dec 23
APDN
Earnings call transcript
2023 Q3
10 Aug 23
APDN
Earnings call transcript
2023 Q2
12 May 23
APDN
Earnings call transcript
2023 Q1
9 Feb 23
APDN
Earnings call transcript
2022 Q4
17 Dec 22
APDN
Earnings call transcript
2022 Q3
11 Aug 22
APDN
Earnings call transcript
2022 Q2
14 May 22
APDN
Earnings call transcript
2022 Q1
10 Feb 22
APDN
Earnings call transcript
2021 Q4
10 Dec 21
APDN
Earnings call transcript
2021 Q3
13 Aug 21
Latest ownership filings
4
Beth Jantzen
27 Mar 23
4
Clay Shorrock
27 Mar 23
4
Judith Murrah
27 Mar 23
SC 13G
AWM Investment Company, Inc.
14 Feb 23
SC 13G/A
Grossman Bruce
9 Feb 23
4
YACOV A SHAMASH
27 Jan 23
4
Scott L Anchin
27 Jan 23
4
Joseph D. Ceccoli
27 Jan 23
4
Sanford R Simon
27 Jan 23
4
Elizabeth M Schmalz
27 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Sep 23 | Sep 22 | Sep 21 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.90 mm | 7.90 mm | 7.90 mm | 7.90 mm | 7.90 mm | 7.90 mm |
Cash burn (monthly) | 1.20 mm | 609.46 k | 1.39 mm | 1.15 mm | 893.26 k | 518.14 k |
Cash used (since last report) | 2.77 mm | 1.41 mm | 3.21 mm | 2.66 mm | 2.06 mm | 1.19 mm |
Cash remaining | 5.13 mm | 6.50 mm | 4.70 mm | 5.24 mm | 5.84 mm | 6.71 mm |
Runway (months of cash) | 4.3 | 10.7 | 3.4 | 4.5 | 6.5 | 12.9 |
Institutional ownership, Q3 2023
20.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 31 |
Opened positions | 5 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 3.20 bn |
Total shares | 2.79 mm |
Total puts | 9.10 k |
Total calls | 91.80 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
AWM Investment | 808.81 k | $994.83 mm |
AMH Equity | 587.23 k | $710.55 mm |
Vanguard | 523.69 k | $633.67 mm |
Susquehanna International | 140.19 k | $172.44 mm |
Hirschman Orin | 140.00 k | $620.00 k |
Geode Capital Management | 139.19 k | $171.26 mm |
BLK Blackrock | 101.66 k | $123.01 mm |
Atria Wealth Solutions | 81.01 k | $98.02 mm |
STT State Street | 75.68 k | $93.08 mm |
Raymond James & Associates | 49.88 k | $60.35 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Mar 23 | Jantzen Beth | Common Stock | Grant | Acquire A | No | No | 0 | 91,667 | 0.00 | 91,739 |
23 Mar 23 | Jantzen Beth | NQSO Common Stock | Grant | Acquire A | No | No | 1.08 | 1,961 | 2.12 k | 1,961 |
23 Mar 23 | Jantzen Beth | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.08 | 98,039 | 105.88 k | 98,039 |
23 Mar 23 | Clay Shorrock | Common Stock | Grant | Acquire A | No | No | 0 | 91,667 | 0.00 | 91,667 |
23 Mar 23 | Clay Shorrock | NQSO Common Stock | Grant | Acquire A | No | No | 1.08 | 1,961 | 2.12 k | 1,961 |
23 Mar 23 | Clay Shorrock | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.08 | 98,039 | 105.88 k | 98,039 |
23 Mar 23 | Murrah Judith | Common Stock | Grant | Acquire A | No | No | 0 | 99,306 | 0.00 | 101,853 |
23 Mar 23 | Murrah Judith | NQSO Common Stock | Grant | Acquire A | No | No | 1.08 | 10,294 | 11.12 k | 10,294 |
23 Mar 23 | Murrah Judith | Incentive Stock Option Common Stock | Grant | Acquire A | No | No | 1.08 | 98,039 | 105.88 k | 98,039 |
25 Jan 23 | Catell Robert B | NQSO Common Stock | Grant | Acquire A | No | No | 1.41 | 39,428 | 55.59 k | 39,428 |
News
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
8 Dec 23
HC Wainwright & Co. Maintains Buy on Applied DNA Sciences, Lowers Price Target to $2
8 Dec 23
Applied DNA Sciences: Q4 Earnings Insights
7 Dec 23
Applied DNA Sciences Q4 EPS $(0.26) Down From $(0.06) YoY, Sales $779.74K Down From $3.56M YoY
7 Dec 23
Earnings Scheduled For December 7, 2023
7 Dec 23
Press releases
Applied DNA Announces Fourth Quarter Fiscal Year 2023 Financial Results
7 Dec 23
Applied DNA to Report Fiscal 2023 Fourth Quarter and Year End Financial Results on December 7, 2023
5 Dec 23
Applied DNA Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application
28 Nov 23
Applied DNA Extends Application of Linea(TM) IVT Platform to saRNA (self-amplifying mRNA)
16 Nov 23
Applied DNA Ships First saRNA (self-amplifying mRNA) IVT Template Generated by Linea(TM) DNA Platform
9 Nov 23